About PYX-106-101 PYX-106-101 (NCT05718557) is an open-label, multicenter, Phase 1 dose escalation trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and ...

PYX-201 and Keytruda combination study in HR+/HER2- breast cancer, TNBC, and sarcoma with preliminary clinical data expected in the second half of 2025 and the first half of 2026.

- Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA® (pembrolizumab) in multiple solid tumors ...

PYX-201-102 (NCT06795412) is a Phase 1/2, open-label, global, multicenter, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and ...

PYX-201 Mechanism of Action (PYXS Corporate Presentation, March 2023.) On March 16, 2023, PYXS announced it had dosed the first patient in its phase 1 trial of PYX-201.

Pyxis evaluated PYX-106 as a monotherapy in a phase 1 trial that enrolled 45 patients with advanced solid tumors. The study, which was still listed as recruiting on ClinicalTrials.gov as of Nov ...

TUCSON, Ariz., June 3, 2025 /PRNewswire/ -- Pyx Health, an engagement company focused on healthcare's most vulnerable, hard-to-reach populations, today announced its acquisition of FarmboxRx, a ...

ANDYs are real-life trained, nonclinical members of Pyx Health's Compassionate Call Center who call a member, find out what's going on, listen and bring in resources if necessary.

The pyx’s decoration, the team determined, draws a connection from the biblical figures of the Old Testament through to what they believe is a depiction of the Ascension of Christ.